All ICD10 Codes

PCS Table XW0

186 procedure codes are mapped to this table.

  • XW00X27Section X

    Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7

  • XW01318Section X

    Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

  • XW01329Section X

    Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • XW01348Section X

    Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

  • XW0136ASection X

    Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10

  • XW01397Section X

    Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

  • XW013F5Section X

    Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

  • XW013G6Section X

    Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013H6Section X

    Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013K6Section X

    Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013L9Section X

    Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • XW013S6Section X

    Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013S9Section X

    Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • XW013T6Section X

    Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013TBSection X

    Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11

  • XW013U6Section X

    Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013V7Section X

    Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

  • XW013W5Section X

    Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

  • XW013W7Section X

    Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

  • XW01X27Section X

    Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

  • XW020D8Section X

    Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8

  • XW023S6Section X

    Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6

  • XW023T6Section X

    Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6

  • XW023U6Section X

    Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

  • XW023V7Section X

    Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7

  • XW023W7Section X

    Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7

  • XW023X7Section X

    Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

  • XW023Y7Section X

    Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

  • XW03308Section X

    Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0330BSection X

    Introduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW0331BSection X

    Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW0333ASection X

    Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW0334ASection X

    Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW03357Section X

    Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03358Section X

    Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0335ASection X

    Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW03367Section X

    Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03368Section X

    Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW03372Section X

    Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2

  • XW03377Section X

    Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03378Section X

    Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW03387Section X

    Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03388Section X

    Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0338ASection X

    Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW03396Section X

    Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW03398Section X

    Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0339ASection X

    Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033A7Section X

    Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033B3Section X

    Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3

  • XW033B7Section X

    Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033BASection X

    Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033C7Section X

    Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033CASection X

    Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033DASection X

    Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033E5Section X

    Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033F3Section X

    Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3

  • XW033F5Section X

    Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033FASection X

    Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033FBSection X

    Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW033G5Section X

    Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033G6Section X

    Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033G7Section X

    Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033H5Section X

    Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033H6Section X

    Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033H7Section X

    Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033J7Section X

    Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033K7Section X

    Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033K9Section X

    Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033L6Section X

    Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033L7Section X

    Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033M7Section X

    Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033MASection X

    Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033N7Section X

    Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033NASection X

    Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033P9Section X

    Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033PBSection X

    Introduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW033Q5Section X

    Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033Q9Section X

    Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033QBSection X

    Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW033R9Section X

    Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033RBSection X

    Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW033S5Section X

    Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033W5Section X

    Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033WBSection X

    Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11

  • XW04308Section X

    Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0430BSection X

    Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW0431BSection X

    Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW0433ASection X

    Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW0434ASection X

    Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW04357Section X

    Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04358Section X

    Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0435ASection X

    Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW04367Section X

    Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04368Section X

    Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW04372Section X

    Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

  • XW04377Section X

    Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04378Section X

    Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW04387Section X

    Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04388Section X

    Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0438ASection X

    Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW04396Section X

    Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW04398Section X

    Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0439ASection X

    Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043A7Section X

    Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043B3Section X

    Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3

  • XW043B7Section X

    Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043BASection X

    Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043C7Section X

    Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043CASection X

    Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043E5Section X

    Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043F3Section X

    Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3

  • XW043F5Section X

    Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043FASection X

    Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043FBSection X

    Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW043G5Section X

    Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043G6Section X

    Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043G7Section X

    Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043H5Section X

    Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043H6Section X

    Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043H7Section X

    Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043J7Section X

    Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043K7Section X

    Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043K9Section X

    Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043L6Section X

    Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043L7Section X

    Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043M7Section X

    Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043MASection X

    Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043N7Section X

    Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043NASection X

    Introduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043P9Section X

    Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043PBSection X

    Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW043Q5Section X

    Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043Q9Section X

    Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043QBSection X

    Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW043R9Section X

    Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043RBSection X

    Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW043S5Section X

    Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043W5Section X

    Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043WBSection X

    Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11

  • XW0534BSection X

    Introduction of Somatic Stem Cells into Peripheral Artery, Percutaneous Approach, New Technology Group 11

  • XW053T9Section X

    Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9

  • XW0632BSection X

    Introduction of CPI-601 Enzyme Replacement Therapy into Cerebral Ventricle, Percutaneous Approach, New Technology Group 11

  • XW0DX38Section X

    Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8

  • XW0DX82Section X

    Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2

  • XW0DXF5Section X

    Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5

  • XW0DXJ9Section X

    Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9

  • XW0DXK8Section X

    Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8

  • XW0DXM6Section X

    Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6

  • XW0DXN9Section X

    Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9

  • XW0DXR7Section X

    Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7

  • XW0DXVBSection X

    Introduction of Xanomeline and Trospium Chloride into Mouth and Pharynx, External Approach, New Technology Group 11

  • XW0E33BSection X

    Introduction of DB-OTO via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11

  • XW0G738Section X

    Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0G7K8Section X

    Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0G7M6Section X

    Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6

  • XW0G7R7Section X

    Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7

  • XW0G886Section X

    Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6

  • XW0H738Section X

    Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0H7K8Section X

    Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0H7M6Section X

    Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6

  • XW0H7R7Section X

    Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7

  • XW0H7X8Section X

    Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0H886Section X

    Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6

  • XW0J3HASection X

    Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0J3JASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0J3KASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0J3LASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0K3HASection X

    Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0K3JASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0K3KASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0K3LASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3HASection X

    Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3JASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3KASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3LASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3HASection X

    Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3JASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3KASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3LASection X

    Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0Q316Section X

    Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6

  • XW0U0GASection X

    Introduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10

  • XW0U0XBSection X

    Introduction of Peptide Enhanced Bone Void Filler into Joints, Open Approach, New Technology Group 11

  • XW0U3XBSection X

    Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Approach, New Technology Group 11

  • XW0U4XBSection X

    Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Endoscopic Approach, New Technology Group 11

  • XW0V0P7Section X

    Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7

  • XW0V3WASection X

    Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10